Zimmer Biomet(US:ZBH)2026-02-19 23:36Sales Performance - In 2025, the company's net sales increased by 7.2% to $8,231.5 million compared to 2024, driven by the acquisition of Paragon 28, market growth, and new product introductions [175]. - The company expects net sales growth of 2.5% to 4.5% in 2026, with the Paragon 28 acquisition contributing an estimated 1.0% to this growth [177]. - In 2025, U.S. net sales grew by 7.3% to $4,764.0 million, with the Paragon 28 acquisition contributing 3.6% to this growth [180]. - International net sales increased by 7.0% to $3,467.5 million in 2025, with foreign currency exchange rates contributing 1.8% to this growth [185]. - The S.E.T. product category saw a significant increase in net sales by 15.2% in 2025, largely due to the Paragon 28 acquisition, which contributed 10.5% to this growth [186]. - Changes in volume and mix of product sales positively impacted year-over-year sales growth by 6.4% in 2025, with the Paragon 28 acquisition contributing 2.5% [182]. Earnings and Expenses - Net earnings for 2025 were $705.1 million, a decline from $903.8 million in 2024, primarily due to inventory charges of approximately $170 million and costs related to acquisitions [176]. - Cost of products sold as a percentage of net sales increased to 30.3% in 2025 from 28.5% in 2024, driven by inventory charges and tariffs [187]. - The company's gross margin decreased to 61.6% in 2025 from 63.8% in 2024, impacted by inventory charges and U.S. tariffs [190]. - Research and development expenses as a percentage of net sales slightly decreased to 5.6% in 2025 from 5.7% in 2024 [187]. - R&D expenses increased in amount but decreased as a percentage of net sales in 2025, driven by Paragon 28-related expenses and higher technology project spending, offset by lower EU Medical Device Regulation compliance costs [191]. - SG&A expenses increased in both amount and percentage of net sales in 2025, primarily due to variable selling and distribution costs, Paragon 28-related expenses, and higher performance-related compensation [192]. - The company recognized $181.2 million in restructuring expenses in 2025, down from $219.0 million in 2024, mainly due to lower costs associated with U.S. and Canada ERP implementation [193]. - Acquisition-related expenses increased in 2025, including $55.1 million for compensation related to Paragon 28 and Monogram acquisitions, partially offset by $77.1 million in net gains from declines in estimated fair values of contingent consideration [194]. Cash Flow and Financial Position - Cash flows from operating activities increased to $1,697.1 million in 2025 from $1,499.4 million in 2024, driven by higher net sales and favorable timing of accounts payable [208]. - Cash flows used in investing activities rose to $1,975.7 million in 2025, including $1,393.2 million for the acquisitions of Paragon 28 and Monogram [209]. - The company had $591.9 million in cash and cash equivalents as of December 31, 2025, with $1.0 billion available under a 364-day revolving credit agreement [206]. Tax and Restructuring - The effective tax rate increased to 15.1% in 2025 from 12.7% in 2024, influenced by foreign rate differentials and intercompany transactions [198]. - The company expects to reduce gross annual pre-tax operating expenses by approximately $175 million by the end of 2027 as part of its restructuring plans [218]. - Management recognized a charge of approximately $170 million to reduce inventory and instruments to their net realizable value due to reduced demand for certain products [225]. Contingent Consideration and Assets - As of December 31, 2025, the company recorded $299.2 million of contingent consideration related to completed business combinations, an increase from $180.7 million in 2024 [237]. - The company had net assets, excluding goodwill and intangible assets, in legal entities with non-U.S. Dollar functional currencies of $1,490.4 million at December 31, 2025 [244]. Risk Management - A sensitivity analysis indicated that a 10 percent change in foreign currency exchange rates could affect earnings by approximately $109 million to $107 million before income taxes [242]. - The majority of the company's debt is fixed-rate, and a 10 percent change in interest rates would not have a material effect on interest expense [250]. - The company is exposed to credit risk primarily from cash and cash equivalents, derivative instruments, and accounts receivable, but believes reserves for losses are adequate [251]. - Management evaluates deferred tax assets on an ongoing basis and provides valuation allowances unless it is "more likely than not" that the deferred tax benefit will be realized [227]. - During the annual goodwill impairment testing in Q4 2025, the estimated fair values of two reporting units exceeded their carrying values by more than 25 percent [232]. - The company enters into supply contracts for raw materials with terms of 12 to 24 months to mitigate commodity price risks [247]. - The company uses derivative financial instruments solely as risk management tools and not for speculative investment purposes [240].